Hyaluronidase
Find information on thousands of medical conditions and prescription drugs.

Vitrase

The hyaluronidases (EC 3.2.1.35) are a family of enzymes that degrade hyaluronic acid.

The enzyme increases tissue permeability, and consequently is used in conjunction with other drugs, to speed their dispersion and delivery. The most common example is opthalmic surgery, where it is used in combination with local anesthetics.

Some bacteria produce hyaluronidase.

In human fertilization, hyaluronidase is released by the acrosome of the sperm cell after it has reached the oocyte. Hyaluronidase aids in digesting proteins in the zona pellucida, thus enabling conception.

Brand names include Vitrase® (ISTA Pharmaceuticals) and Wydase®.

Home
Diseases
Medicines
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
Hydrocodone
Vagifem
Valaciclovir
Valcyte
Valganciclovir
Valine
Valium
Valnoctamide
Valproate semisodium
Valproic acid
Valpromide
Valrelease
Valsartan
Valstar
Valtrex
Vancenase
Vanceril
Vancomycin
Vaniqa
Vanticon
Vecuronium bromide
Velcade
Velivet
Venlafaxine
Ventolin
Vepesid
Verapamil
Verelan
Vermox
Versed
Vfend
Viadur
Viagra
Vicoprofen
Vidarabine
Vidaza
Videx
Vigabatrin
Viloxazine
Vinblastine
Vincristine
Vinorelbine
Viomycin
Vioxx
Viracept
Viread
Visine
Vistide
Visudyne
Vitaped
Vitrase
Vivelle
Volmax
Voltaren
Voriconazole
Vosol
W
X
Y
Z

Read more at Wikipedia.org


[List your site here Free!]


Ista Pharmaceuticals, Inc. [dagger]: FDA Advisory Committee to consider ISTA Pharmaceuticals' Vitrase(R) on March 17, 2003. (Equities reporter: Advertising). : An article from: Equities $5.95

ISTA Pharmaceuticals Announces Phase III Data Demonstrating that a Single Intravitreous Injection of VITRASE® Results in Improved Visual Acuity
Findings Presented in Poster Session during 109th American Academy of Ophthalmology Annual Meeting in Chicago, Illinois IRVINE, Calif., Oct. 20 /PRNewswire-FirstCall/ ...
ISTA Pharmaceuticals Announces VITRASE® Spreading Agent and Adjunct Clinical Data Presentations for Fall 2005
IRVINE, Calif., Sept. 19 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. today announced its Fall 2005 schedule for presenting clinical data on its product, Vitrase(R) (Ovine Hyaluronidase),
ISTA Pharmaceuticals Announces Date for Release of Phase III Clinical Trial Results of Vitrase for the Treatment of Severe Vitreous Hemorrhage
Medical & Health Writers IRVINE, Calif.--(BW HealthWire)--Dec. 10, 2001 ISTA Pharmaceuticals(TM), Inc. (Nasdaq: ISTA), today announced that on January ...
Advanced Corneal Systems Begins North American Phase III Study of Vitrase, a Novel Nonsurgical Treatment for Vitreous Hemorrhage
IRVINE, Calif.--(BW HealthWire)--Nov. 23, 1998--Advanced Corneal Systems, Inc. (ACS) today announced today that the company has initiated a Phase III ...
Advanced Corneal Systems' Vitrase for Treatment of Vitreous Hemorrhage Receives FDA Fast Track Designation
IRVINE, Calif.--(BW HealthWire)--Oct. 15, 1998--Advanced Corneal Systems, Inc. (ACS) today announced that the company's investigational drug Vitrase(tm), ...
Phase III Clinical Trial Results Support Ability of Vitrase to Safely and Effectively Clear Vitreous Hemorrhage
IRVINE, Calif.--(BW HealthWire)--June 25, 1998--Advanced Corneal Systems, Inc. ("ACS") announced that clinical data presented at the 28th International ...
Advanced Corneal Systems Files for Vitrase Approval in Mexico
IRVINE, Calif.--(BW HealthWire)--June 2, 1998--Advanced Corneal Systems, Inc. (ACS) today announced that its Registration Submission for Pharmaceutical ...
ISTA Pharmaceuticals Reports Third Quarter 2005 Financial Results
IRVINE, Calif., Nov. 8 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. today reported its unaudited financial results for the third quarter ended ...

Home Contact Resources Exchange Links ebay